Eli Lilly says it plans to submit orforglipron to the U.S. Food and Drug Administration for approval as a Type 2 diabetes treatment in 2026. For weight management, it plans to submit the drug to ...

Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes patients lower blood sugar—and even reduce weight, bringing an oral version of the booming class of drugs ...

Injectables for type 2 diabetes and weight loss could soon be a thing of the past. Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small ...

A daily pill from drugmaker Eli Lilly has shown similar effectiveness ... The once-daily pill, called orforglipron, helped patients with Type 2 diabetes during late-stage trials and has shown ...

(CNN) — Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 diabetes lose an average of nearly 8% of their body weight after ...

The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes patients lower blood sugar—and ...

April 17 (UPI) --People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its latest clinical testing, the Indianapolis-based drugmaker ...

with an 8% dropout rate at the highest dose. Eli Lilly plans to file for regulatory approval in diabetes by 2026 and in obesity by late 2025.

Lilly said its new pill would continue the company's "mission to reduce chronic diseases like type 2 diabetes," which it says is expected to roughly impact 760 million adults by 2050. During the ...